However, PARP1 inhibition and the subsequent synthetic lethality can be used on other cancers that do not have mutations in BRCA1 or BRCA2 but that have a defect in the HR pathway, including mutations in ATM, Chk2, Rad51, and NBS1. Here, ATM is linked to cancer.